Darbepoetin Alfa
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Darbepoetin Alfa |
| DrugBank ID | DB00012 |
| Brand Names (EU) | Aranesp |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 96.73% |
Approved Indication (EMA)
Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients. Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | amenorrhea (disease) | 96.73% | DL |
| 2 | renin-angiotensin-aldosterone system-blocker-induced angioedema | 96.46% | DL |
| 3 | anaphylaxis | 93.15% | DL |
| 4 | psoriasis | 92.70% | DL |
| 5 | penile fibromatosis | 92.17% | DL |
| 6 | food-dependent exercise-induced anaphylaxis | 91.97% | DL |
| 7 | Peyronie disease | 91.94% | DL |
| 8 | Ledderhose disease | 91.14% | DL |
| 9 | infantile digital fibromatosis | 91.06% | DL |
| 10 | HER2 positive breast carcinoma | 90.90% | DL |
| 11 | palmar fibromatosis | 90.30% | DL |
| 12 | scalp dermatosis | 90.15% | DL |
| 13 | pityriasis lichenoides | 89.23% | DL |
| 14 | seborrheic dermatitis | 88.43% | DL |
| 15 | normal breast-like subtype of breast carcinoma | 88.11% | DL |
| 16 | progesterone-receptor positive breast cancer | 88.11% | DL |
| 17 | breast tumor luminal A or B | 87.84% | DL |
| 18 | progesterone-receptor negative breast cancer | 87.41% | DL |
| 19 | autoimmune hemolytic anemia | 86.90% | DL |
| 20 | dermatitis | 86.28% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.